Life Sciences Archive » January, 2024

Life Sciences - January, 2024

376 articles

• Fluoride Risk Trial Opens With Claim Exposure Drops Kids' IQ
• FibroGen's $28.5M Deal With 30K Investors Nears Tentative OK
• FDA Adopts ISO Standard For Device Makers In New Rule
• Cooley-Led Vaxcyte Prices $750M Public Offering
• Cardinal Health Buys Specialty Networks In $1.2B Deal
• Norton Rose-Led FibroBiologics Pulls Off Direct Listing
• Supernus Wins Ban On Generic Seizure Treatment
• Fed. Circ. In Jan.: One Word Can Affect Claim Construction
• FDA Seeks Max Fines Against Shops Selling Esco Bars Vapes
• NJ Law Firm Seeks Sanctions In Malpractice Suit Led By Rival
• 5 Reasons Associates Shouldn't Take A Job Just For Money
• Gunderson Practice Head Boosts Orrick's Life Sciences Team
• Ex-Pfizer Compliance Officer Revamps Whistleblower Suit
• Scholars, Advocates Tell Justices Mifepristone Limits Must Go
• 1st Circ. Backs Doctor In Row Over Patent Evidence
• CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
• Trans Care Ban Poses 'Philosophical' Questions, Justices Say
• Pharmacy Knew Conn. Kickbacks Broke Law, Founder Testifies
• Can Brain Scans Build On Consumer Surveys In IP Disputes?
• Philips Halts Sales Of Sleep Apnea Devices In US After Recall
• Milan Becomes 3rd Seat Of Unified Patent Court Division
• Pro Bono Patent Program Attracts Many Female Applicants
• Allergan Asks 9th Circ. To Ignore Atty's Claims Of Fraud
• 7th Circ. Won't Revive School Staffers' COVID-Testing Suit
• How Biotech Deals May Help Competition, Despite FTC View
• Expediting Psychedelics Approvals In The US And Canada
• Stryker Can't Slip California Workers' Wage Suit
• Pfizer Says Moderna Telling FDA One Thing, PTAB Another
• Troutman Pepper Gains McGuireWoods Securities Pros In NC
• Guardant Diagnostics Patent Survives PTAB Challenge
• Playing Competitive Tennis Makes Me A Better Lawyer
• CareDx Hit With $96M Infringement Verdict Over DNA Test IP
• Don't Keep Us Out Of ITC, Startup Says In Apple Watch Row
• HHS Urges Court To Reject Novo Nordisk Drug Plan Challenge
• Hearing Aid Co. Eargo Investors Ask 9th Circ. To Revive Suit
• Justices To Hear Abortion Drug Case Arguments In March
• The Top Attys In Clinton's Impeachment Trial, 25 Years Later
• Feds Drop Insider Trading Charges Against Ex-Mylan Exec
• The Pop Culture Docket: Judge Djerassi On Super Bowl 52
• 2 Biotech Firms Join IPO Fray With Plans To Raise $211M
• McCarter & English Urges Against Updating Malpractice Suit
• Reverse Merger Tips For Biotechs After SEC's Recent Actions
• Judge Might Screen Stimwave Ch. 11 Filings To Avoid 'Chaos'
• Imperative Care Names O'Melveny Deals Partner As CLO
• Catching Up With Delaware's Chancery Court
• White & Case Loses Another IP Partner To Cahill Gordon
• GSK Unit Pauses Chancery Patent Suit For Settlement Talks
• Generic-Drug Co. Concedes Infringement In Pfizer Heart Med Row
• Justices Urged To Bar Infringement Rulings After PTAB Ax
• Dissolved Biomed Co. Aims To Bar Ex-CEO's Credit Bid In Del.
• Tenn. Couple Sentenced For $65M Tricare Fraud
• Chancery Hits Hedge Fund With Sanctions In Bioverativ Case
• 2nd Circ. Backs Catholic Health System's Win In Bias Suit
• Law360 Seeks Members For Its 2024 Editorial Boards
• Panel Backs AG's Power To Nix Claims In $26B Opioid Deal 
• Ex-Goodwin Procter Life Sciences Atty Joins DLA Piper In NY
• NYC Man Gets 5 Months In Merck, Pandion Insider Trading Case
• UK Litigation Roundup: Here's What You Missed In London
• Petition Watch: Patent Obviousness, ADA Trials, Spoofing
• Opioid Nuisance Query Better For W.Va. Court, 4th Circ. Hints
• Invisalign Maker Says Deal With Rival Was Lawfully Ended
• Lawmakers Push Back On Biden's Support For TRIPS Waiver
• Danaher Execs Face Investor Suit Over Post-Pandemic Slump
• Eye Care Tech Co. Gets Tentative OK For $8M DIP
• Norton Rose-Led FibroBiologics Plans Direct Listing Over IPO
• Ex-Director Says Off-Label Marketing Objections Cost Him Job
• Proposed Rule Misses The Mark On Improving MDLs
• Taking A Closer Look At Fed. Circ. Claim Construction Split
• Morgan & Morgan Beats Firms To Lead Zoll Data Breach Row
• The 7th Circ.'s Top 10 Civil Opinions Of 2023
• Employee Experience Strategy Can Boost Law Firm Success
• Med Device Employee Gets 1 Year For Forging FDA Clearance
• Latham, Cooley Steer CG Oncology's Upsized $380M IPO
• Bid To Swap Chevron For An Old Standby Raises Doubts
• Pot Insurance Suit Belongs In Federal Court, Judge Says
• Feds Ask Justices To Nix 5th Circ.'s Abortion Pill Limits
• Orrick Brings In First-Chair IP Trial Lawyer From Venable
• Amyris Says Claim Releases Needed For Post-Ch. 11 Success
• $15M Bayer Deal Gets Early Nod, But Fees Concern Judge
• Texas Judge Orders SmileDirectClub To Convert To Ch. 7
• Elmo Can't Save Parents' COVID-19 Vax Suit, 5th Circ. Says
• Florida Findings Loom Large In Del. Zantac Tort Suit
• Competing In Triathlons Makes Me A Better Lawyer
• Parsing The USPTO's Guidelines For Assessing Enablement
• Cahill Gordon Adds Life Science IP Leader From White & Case
• Notes Of Interest From 5th Circ. Illumina-Grail Merger Ruling
• UK Billionaire Joe Lewis Pleads Guilty To Insider Trading
• Danco Asks Justices To Reject 5th Circ.'s Abortion Pill Limits
• 3 Generic-Drug Cos. Reach Settlements In Price-Fixing MDL
• Wash. AG Seeks Toss Of Clinics' 'Abortion Pill Reversal' Case
• Senators Hear Praise And Worry About Patent Eligibility Bill
• Pharma Co. Must Face Investor Suit Over Cancer Drug Study
• UPenn's Retrial Bid Is Denied In $183M Birth Injury Case
• Teva Can't Escape Insurers' Copaxone Generic Delay Case
• DOJ Seeks Dismissal Of Challenge To Federal Cannabis Ban
• Del. Judge Nixes Bidder Fees In Humanigen Ch. 11
• W.Va. County To Face Off With Opioid Distributors At 4th Circ.
• Ex-CEO's Counterclaims Not Allowed, Insys Trustee Says
• DOJ's Biopharma Settlement Raises Anti-Kickback Questions
• 3 States Ask To Join High Court Case Against Abortion Drug
• Where Justices Stand On Chevron Doctrine Post-Argument
• Fed. Circ. Sends Xencor Antibody Patent Case Back To USPTO
• Precise Advance Notice Bylaws May Help Prevent Disputes
• Upsized CG Oncology IPO Could Raise As Much As $306M
• Ballard Spahr Privacy Team Co-Leader Jumps To Blank Rome
• Mayer Brown Adds Another Wilson Sonsini Litigator In Calif.
• Former Police Chief Cops To Insider Trading Charges In NY
• 2nd Circ. Backs Shkreli Lifetime Pharma Industry Ban
• 6 Practice Pointers For Pro Bono Immigration Practice
• Weil Helps Sanofi Buy Rare Diseases Co. For Up To $2.2B
• Anesthesiologists Want Quick Ruling On Medicare Calculation
• Ex-Greenberg Traurig IP Pro Joins McCarter & English
• Investors Sue Biopharma Co. After Clinical Trial Data Toss
• Mallinckrodt Trust Can Pursue Covidien Clawback Claims
• Zantac Class Attys Urge Del. Judge To Keep Experts In Case
• 3 Takeaways From Health Officials' Marijuana Proposal
• Biden Rolls Out New Abortion Protections On Roe Anniversary
• Moderna Wants UPenn Biochemist's Emails In Vax IP Dispute
• Ex-Director Denies Agreeing To Keep Pharma Firm's Info Secret
• Medical Software Co. Eye Care Leaders OK'd For Joint Ch. 11
• FTC Fights Bids To Toss Texas Anesthesia Roll-Up Case
• ESG Around The World: Canada
• Motley Rice Fights DQ Bid In Opioid MDL
• Cancer-Focused Arrivent Biopharma Eyes $150M IPO
• HIV Drug Wholesalers' Attys Get $75M In Gilead Antitrust Case
• Skin Care Drug Co. Timber Gets OK For Ch. 11 Sale To Lender
• Fish & Richardson Adds Ex-Patent Judge To Firm
• 5 Legal Considerations For Psychedelic Therapy Sector
• Catching Up With Delaware's Chancery Court
• Lessons From Country Singer's Personal Service Saga
• Red Cross Has Antitrust Immunity, Judge Rules
• Chinese Co. Can't Avoid Contempt In Philips X-Ray IP Suit
• Boston Biopharma Co. Picks Industry Veteran As Next GC
• Feds Want 30 Months For Trader In BigLaw Info Theft Case
• Sandoz To Acquire Retinal Disease Biosimilar For $170M
• Law360 Names Firms Of The Year
• Law360 Names Practice Groups Of The Year
• Claims Court Judge Doubts Takings Clause Applies To Pharma IP
• Klobuchar Tells Drug Cos. To Act On FTC Patent Warnings
• Ex-Pharmacy Head Gets 3 Years For $32M Telemed Scheme
• Kenvue Execs, J&J Face 2nd Investor Action Over FDA Probe
• Becton Investors Get Initial OK Of $85M Deal Over Recall
• Convertible Bonds Gain Momentum Amid Elevated Rates
• Feds Maintain Glycine Duty Evasion Stance, Despite New Info
• Delay In Award Boosts Philly Birth Injury Verdict To $208M
• Biotech Investor Sues In Del. For Info On 'Unfair' Repricing
• A Potential Proactive Tool For Public-Private Joint Ventures
• Winston & Strawn Dodges Sanctions In NC Pharma Fight
• Quest Diagnostics Settles Billing Practices Suit
• UK Litigation Roundup: Here's What You Missed In London
• SmileDirectClub Pushes Ch. 11 Wind-Down, Fights Ch. 7 Bids
• Stimwave's Ex-CEO Wants Bankruptcy Case Stayed
• CG Oncology Aims To Raise Up To $212M As It Sets IPO Terms
• Committee May Subpoena J&J, Merck CEOs Over Drug Costs
• Del. Court To Open Early Round In Massive Zantac Litigation
• SEC, US Trustee Object To Releases In Amyris' Ch. 11 Plan
• 7th Circuit Probes Damages Evidence In Kickback Suit
• BridgeBio Pharma Secures $1.25B For New Drug Launch
• Patent Prosecution Carries Consequences For Later Litigation
• Quinn Emanuel Says Judge Is Right To Block Subpoena
• LegitScript Wants Quick Appeal In Price-Checker Antitrust Suit
• 10 Global Antitrust Trends To Anticipate In 2024
• NanoString Says Doubled Award Would Be 'Death Sentence'
• Ex-Pfizer Worker Convicted In Paxlovid Insider Trading Case
• MoFo Says 2024 Rate Cuts Will Boost PE's M&A Appetite
• 'Chaos' Warning Resonates As Justices Mull Chevron's Fate
• Thomas Gets Laugh, Agrees Prior Ruling Is 'Embarrassment'
• 5 Key Takeaways From Supreme Court's Chevron Arguments
• FDA Can't Publish Unsupported Concerns About Pharmacy
• 10th Circ. Probes Challenge To Okla. Trans Care Ban
• Eye Care Software Co. Seeks Ch. 11 With Up To $1B Debt
• PTAB Nixes Seagen Cancer Drug IP After Daiichi Verdict
• Pharma Challenge To Advisory Anti-Kickback Opinion Tossed
• Boston's Ratio Therapeutics Raises $50M Series B For R&D
• Generic-Drug Cos. Say States Are Mum In MDL Discovery
• Judge Orders Explanation For Continuing Tylenol MDL Cases
• Sandoz Asks Fed. Circ. To Wipe Out Allergan's $39M IP Award
• Apple Drops Blood Oxygen Tech From New Watches After Ban
• Brown Rudnick Launches Life Sciences Consulting Division
• Ex-Pfizer Worker's 'Stupid' Trades Still Fraud, Jury Told
• Global Cartel Enforcement Looks Set To Intensify In 2024
• Baking Bread Makes Me A Better Lawyer
• High Court Majority Shows No Eagerness To Overturn Chevron
• J&J Consumer Inc. Hit With Neutrogena Preservatives Suit
• 6 Opinions To Read Before High Court's Chevron Arguments
• Pfizer Calls Moderna 'Willfully Naïve' In Covid Vax IP Fight
• Stimwave Trustee Seeks To Sanction Founders In Del. Ch. 11
• Jury Awards $57M To Ravgen In Genetic Test Patent Row
• Sen. Tillis Warns Biden Against Seizing Drug Patents
• Manatt Adds Health Policy Strategist In DC Office
• Apple Rips ITC, Masimo In Bid To Keep Original Watch On Sale
• Biotech Startup Alto Neuroscience Files To Go Public
• Supreme Court Amgen Ruling's Major Effect On Enablement
• Federal Courts And AI Standing Orders: Safety Or Overkill?
• Widow Targets Buchanan Ingersoll Atty In $7.5M Policy Spat
• Chancery Bars Icahn Co. Use Of Some Illumina-Grail Docs
• Crowell Adds Moses Singer Health Trio In New NYC Office
• Apple Cleared To Avoid Import Ban With Redesigned Watch
• Canada, Pharma Opposition Loom Over Fla. Drug Imports
• Vanda Asks Justices To Undo Ruling In Sleep Drug IP Case
• Conn. AG Revises Settlements For Drug Kickback Defendants
• Va. Abortion Drug Access Suit Paused For High Court Rulings
• HHS Unveils Schedule III Recommendation For Marijuana
• Apple Loses 2 Masimo Patent Challenges At Fed. Circ.
• IPO Pipeline Starts To Unclog As New Filings Gain Steam
• Vyera Ch. 11 Trustee Wants To Claw Back $10M From Supplier
• Lab Says COVID-19 Test-Maker Owes $30M Over Faulty Kits
• 7 E-Discovery Predictions For 2024 And Beyond
• Judge OKs Bid By 3 States To Join Suit Against Abortion Drug
• Drug Cos. Question FDA Off-Label Communications Guidance
• High Court Eyes Chevron Deference: What You Need To Know
• Top Considerations For Retailers Using AI To Combat Theft
• Taxation With Representation: Kirkland, Latham, Wachtell
• NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
• Medicare Drug Price Talks Encourage Competition, Court Told
• Stephenson Harwood Adds 2 Partners In Hong Kong Office
• Natera Can't Escape Ravgen's Patent Infringement Suit
• Petition Watch: Atty 1st Amendment Rights, ERISA Remedies
• Quest Fertility Biz Reaches $1.25M Deal In Data Breach Case
• Eye Software Rivals Settle IP Fight Ahead Of February Trial
• Fed. Circ. Asked To Resume Ban On Apple Watch Imports
• Deals Rumor Mill: Ripple Labs, Match, Novartis
• Medtech Co. Integer To Buy Pulse Technologies For $140M
• 2 FCPA Settlements Illuminate Self-Disclosure, Disgorgement
• DOD Finds Violations Rife At White House Med Unit Pharmacy
• Union Funds Exit Amgen, Teva Antitrust MDL
• Hedge Fund Priest Seeks Atty Fees After Mixed SEC Verdict
• 2 Apple Wins Against Masimo Upheld By Fed. Circ.
• Gilead To Face 'Morally Blameworthy' Claim In HIV Drug Fight
• HHS Taps Official To Promote Competition In Healthcare
• Bill Floated To Study Bayh-Dole Requirement Inefficiencies
• Rex Medical Asks Fed. Circ. To Decry Slashing Of $10M Award
• Troutman Pepper Adds New Member To DC Health Practice
• Mass. Facility Using Once-Barred Shock Devices Sues FDA
• CNS Startup Myrobalan Therapeutics Raises $24M Series A
• AliveCor Gets PTAB To Look Into Apple Patents At Issue In Suit
• FDA Tells 5th Circ. To Toss Suit Over Kids' COVID-19 Shots
• Anti-Kickback Statute Does Not Require But-For Causation
• Fed. Circ. Affirms PTAB Rulings In Genomics Row
• FDA 'Can't Do This Alone,' Wants Help Vetting AI In Healthcare
• 'Giant Hole' In Pfizer Insider Trading Case, Jury Told
• NJ Lab, Owner To Pay $13M To Settle Kickback Claims
• Class Claims Aren't About Food Fraud, NJ Justices Say
• 5 Litigation Funding Trends To Note In 2024
• Vape Distributor Can't Get Quick Win In Contract Dispute
• Texas Atty Beats Perjury Convictions, But Other Counts Stand
• FDA Digital Tech Rule Faces Health Privacy, Inequity Test
• Ohio High Court Urged To Toss $650M Opioid Verdict
• VC Firm Expands Collaborations In New Tech Initiative Debut
• Amyris Fights Claims In Cannabis IP Row By Defining 'Under'
• Deal Language Irks Judge As $11M False Claims Trial Begins
• HHS Updates Religious, Moral Objection Rule For Doctors
• Health Groups Urge Texas Justices To Nix Trans Youth Care Ban
• Biopharma Co. Can't Dodge Secrets Row Over Detox Drug
• Home Health Co. Faces ERISA Suit Over Smoking Surcharge
• Air Force Can Sole-Source Medical Infusion Pump Updates
• USPTO Affirms Amgen Ruling Didn't Alter Experimentation Test
• Attys Seek $95M Fees For Philips CPAP Economic Loss Deal
• Medtronic's Cautionary Tale Of Fed. Circ. Word Limits
• GSK Agrees To Buy US Respiratory Drug Biz For Up To $1.4B
• Supreme Court Is Suddenly Embroiled In A Term For The Ages
• Senators To Probe Pharma Cos. On 'Outrageous' Inhaler Costs
• Teva, Israeli Investors End Investor Suit Over Opioid Scandal
• Future Apple Watch Sales Hinge On Next Steps In Patent Row
• Proskauer Picks Up IP Partner From Frankfurt Kurnit
• Baker Botts Bond Took Antitrust Pros To Wilson Sonsini
• FDA Advice Prompts Shareholder Suit Against J&J, Execs
• Key Legal Trends For Healthcare And Life Sciences In 2024
• Catching Up With Delaware's Chancery Court
• Humanigen Gets Access To New Cash For Ch. 11 Process
• Merck Lands Cancer Fighter Harpoon Therapeutics For $680M
• Pharma Co. Overstated Unpatented Drug's Value, Suit Says
• Novartis To Buy Merck Spin-Off Calypso Biotech For Up To $375M
• Eli Lilly, Novartis Could Pump Close To $3B Into AI Drug Tech
• ImmunoGen Undervalued In AbbVie Deal, Shareholder Claims
• Ex-Dechert Litigator Joins Seeger Weiss In Philadelphia
• Walgreens, Humana Cut $360M Deal Ending Crowell Fight
• ESG Around The World: South Africa
• Biofuel Co. Ryze Gets OK On Ch. 11 Wind-Down Plan
• Cravath Steers J&J Buy Of Skadden-Led Ambrx In $2B Deal
• Boston Scientific To Buy Medtech Co. Axonics In $3.7B Deal
• GE HealthCare To Buy AI-Powered MIM Software
• Justices Won't Take Up DOD, Ex-Sergeants Vax Mandate Spat
• Justices Refuse To Eye PTAB's Fintiv Review Denial Policy
• Idaho AG Again Denied Immunity In Abortion Travel Ban Fight
• Drug Kickback Case Lineup In Flux As Trial Looms
• Eli Lilly Goes Straight To Consumers With Telehealth Platform
• Pharma Co. Snags $100M To Advance Psychedelic Treatment
• Split 9th Circ. Revives Antitrust Suit Against Catheter Maker
• Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
• ​​Boehringer Ingelheim Inks €410M Deal With Kyowa Kirin
• 9th Circ. Won't Rethink FCA Disclosure Ruling Against Valeant
• NJ Brothers Ordered To Prison For Prescription Drug Scheme
• Philips Blames SoClean For Breathing Machine Breakdowns
• Attys Hopeful For Deals Pickup As JPMorgan Event Kicks Off
• Former Alexion Exec Avoids Prison In Insider Trading Case
• FOIA Exemption Questions On Redacted HHS Cannabis Letter
• Fed. Circ. Ruling Seemingly Offers PTAB Deadline Immunity
• Evaluating Retroactivity Of Mich. Drugmaker Immunity Repeal
• 4 Legal Ethics Considerations For The New Year
• McCarter & English Accused Of Obstructing Malpractice Case
• FTC Rite Aid Order Holds Biometrics And AI Compliance Tips
• Bribery Settlement Gives Insight On DOJ Policies
• SEC Case May Expand Scope Of Insider Trading Liability
• UK Litigation Roundup: Here's What You Missed In London
• Fla. Becomes 1st State To Win FDA Approval To Import Drugs
• Where Psychedelics Policy Is Going In 2024
• No Evidence Of Harm: ITC Denied Apple's Watch Ban Stay
• Birth Control Clips Hurt Women When They Move, Suit Says
• Humanigen Hits Ch. 11 After COVID Drug Denied Authorization
• Roche Could Pay $2B In Deal To Develop Potent Cancer Drugs
• Small Vape Cos. Ask Court To Block FDA Premarket Rule
• Life Sciences Investment Firm TCG Crossover Closes $1B Fund
• 2 Couples Sue CooperSurgical After Embryo Solution Recall
• LegitScript Can't Nix PharmacyChecker Antitrust Suit
• Waiving COVID-19 IP Protections Would Harm US Industry
• Assisted Living Brass May Have Caused Late Suit, Judge Says
• McCarter & English Rips Bid To Bring New Malpractice Claims
• Ex-Shook Hardy IP Pro Named USPTO's Chief Policy Officer
• Chancery Rejects Injunction Barring SomaLogic Merger Vote
• Ex-CEO Of Texas Biotech Co. Sues It In Del. For Legal Fees
• Deals Rumor Mill: Cigna, Bain Capital, Amazon
• Fed. Circ. Patent Decisions In 2023: An Empirical Review
• What The Law Firm Of The Future Will Look Like
• Medical Tech Co. Buys Breathing Device Biz For Up To $2.5M
• Judge Won't Dismiss Botox Trade Secret Dispute
• Univ. Of Pittsburgh Sued By Fired Worker Who Flagged Safety
• Galderma Labs Seeks OK Of Award Over Botox-Like Treatment
• Sporting Goods Co. Can't Shake Football Helmet Patent Case
• Wellness Co. Sues Theragun Maker For Patent Infringement
• Chancery Mulls Call To Block $1B SomaLogic Merger
• Esperion Snags $125M Deal With Daiichi On Cholesterol Drug
• Conn. AG, Alleged Drug Kickback Ringleader Ink $230K Deal
• Judge Pauses Apple Patent Suit Ahead Of PTAB Decision
• BioXcel Execs Face Investor Suit Over Alzheimer's Drug Probe
• 10th Circ. Denies Okla. Stay Request In PBM Law Fight
• 4 PR Pointers When Your Case Is In The News
• Hemp Industry Urges Congress To Make Policy Changes
• Witness On Hair Loss, Rashes DQ'd In Flint Case As Unreliable
• FDA Seeks Comment On Ideas To Improve Agency Guidance
• Fed. Circ. Backs Refusal To Block Abbott IPRs Of DexCom IP
• Digging Into The Debate On FDA's Proposed Lab Test Rule
• Myovant, Sumitomo Beat Investor Suit Over Skadden Advice
• Medicare Fraud Player Slams Feds' 'Excessive' Prison Ask
• Lye Buyers Denied Class Cert. In $861M Price-Fixing Fight
• Health Service Co., Oncology Firm Kick-Start 2024 IPO Filings
• You Can't Double Dip The Patents, Judges Told
• HHS OIG Won't Levy AKS Fines For Subsidies In Clinical Trial
• Teva Can't Block Colo. EpiPen Program Over Takings Claim
• Regulators Approve NYSE Plan To Ease Rules On Equity Sales
• How 2023 Shaped Drug And Medical Device Legal Trends
• UK Biopharmaceutical Biz Raises $260M In Series C Funding
• Catching Up With Delaware's Chancery Court
• Pa. Court Rejects Red Book Drug Prices For Workers' Comp
• Consumer Health Activist And Author Sidney Wolfe Dies At 86
• What Insurers Gain When Litigating Coverage Denials
• Trending At The PTAB: 6 Areas To Watch In 2024
• Infant Formula Recalled After Possible Contamination
• Chancery Dissolves Biomed Co. For 'Egregious' Conduct
• 5 Trends That Will Affect Food Litigation In 2024
• New Hampshire Residents Nab Class Cert. In PFOA Suit
• Patent Litigation Trends To Watch In 2024
• 5 Supreme Court Cases To Watch This Spring
• Patent Policy To Watch In 2024
• Michigan Cases To Watch In 2024
• Law Firm Strategies For Successfully Navigating 2024 Trends
• Bankruptcy Issues To Watch In 2024
• Will The DOJ Reschedule Cannabis In 2024?
• Patent Cases To Watch In 2024
• Trials To Watch In 2024
• Product Liability Regulation And Legislation To Watch In 2024
• Top North Carolina Cases To Watch In 2024
• Connecticut Cases To Watch In 2024
• Product Liability Cases To Watch In 2024
• Appellate Outlook: Circuit Splits & Hot Topics To Track In 2024
• 'Pent Up' Demand For IPOs Could End Drought In 2024